Ovarian Cancer

Mary-Claire King, PhD, will receive the William L. McGuire Memorial Lecture Award at this year’s San Antonio Breast Cancer Symposium, which will be held Dec. 8-12.

The FDA granted fast track designation to XMT-1536 for the treatment of women with high-grade serous ovarian cancer, according to a press release from the agent’s manufacturer.

Women who underwent chemotherapy or surgery for gynecologic cancer and also had COVID-19 infection did not appear at significantly increased risk for death due to the novel coronavirus, according to study findings published in Cancer.

Immunotherapy did not appear to worsen complications among patients with cancer and COVID-19, according to results of a study presented at American Association for Cancer Research Virtual Meeting: COVID-19 and Cancer.

Overall survival results from SOLO-2 showed patients with recurrent ovarian cancer and germline BRCA mutations added a year of life when treated with olaparib only, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

Though the combination of cediranib and olaparib did not beat out platinum-based chemotherapy, it was more effective in patients with germline BRCA mutations, according to Ursula A. Matulonis, MD, of Dana Farber Cancer Institute.

Studies presented during the ASCO2020 Virtual Scientific Program showed the benefit of validated selection tools in pursuing surgical measures for ovarian cancer relapse, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

A study presented during the ASCO2020 Virtual Scientific Program showed ‘impressive’ use of immunotherapy for gestational trophoblastic disease, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

The addition of berzosertib to gemcitabine extended PFS for women with platinum-resistant, high-grade serous ovarian cancer, according to results of a randomized phase 2 study published in The Lancet Oncology.

According to projections from the National Cancer Institute, COVID-19 will result in 10,000 additional deaths due to breast cancer and colorectal cancer over the next 10 years. This was the top story in hematology/oncology last week.